

Special Issue

Advanced Research on Immune Checkpoint Inhibitor Therapy

Message from the Guest Editor

Many patients die from cancer, but with the recent advent of immune checkpoint inhibitors, some patients have shown dramatic therapeutic effects. Although the treatment of cancer has become complicated due to the emergence of immune checkpoint inhibitors, the prognosis of patients has been prolonged, and treatment is improving day by day. We have decided to launch a Special Issue at this time on “Advanced Research on Immune Checkpoint Inhibitor Therapy”. This Special Issue will highlight and summarize the current knowledge concerning “Advanced Research on Immune Checkpoint Inhibitor Therapy”, covering both basic and (pre)clinical aspects. Potential studies may include assessment of “Advanced Research on Immune Checkpoint Inhibitor Therapy”. For this Special Issue, we invite investigators to contribute original articles as well as review articles that will describe and help in understanding the current and potential challenges surrounding this topic.

For further information, please visit https://www.mdpi.com/journal/jcm/special_issues/Immune_Checkpoint_Inhibitor_Therapy

Guest Editor

Dr. Hisao Imai

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City 350-1298, Saitama, Japan

Deadline for manuscript submissions

closed (31 December 2021)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/si/85329](https://www.mdpi.com/si/85329)

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

[mdpi.com/journal/](https://www.mdpi.com/journal/)

[jcm](https://www.mdpi.com/journal/jcm)





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).